ArticleVaccine2010
Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma.Journal of translational medicine · 2014Trial
- M13 phage-based antigen presentation and immune response activation in vaccine development for animal infectious diseases.Frontiers in immunology · 2026Review
- Article
- Engineered Bacteriophages: Advances in Phage Genome Redesign Strategies for Therapeutic and Environmental Applications.Protein and peptide letters · 2025Review
- Novel SARS-COV2 poly epitope phage-based candidate vaccine and its immunogenicity.Research in pharmaceutical sciences · 2024Article
- An Engineered M13 Filamentous Nanoparticle as an Antigen Carrier for a Malignant Melanoma Immunotherapeutic Strategy.Viruses · 2024Article
- Review
- Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease.NPJ vaccines · 2022Article
- The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.Pharmaceutics · 2022Review
- Bacteriophages as Therapeutic and Diagnostic Vehicles in Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Review
- Bee Venom Immunotherapy: Current Status and Future Directions.Clinical reviews in allergy & immunology · 2020Review
- Phage Display-Based Nanotechnology Applications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2020Review
- Function of the RNA Coliphage Qβ Proteins in Medical In Vitro Evolution.Methods and protocols · 2018Review
- Microbial Delivery Vehicles for Allergens and Allergen-Derived Peptides in Immunotherapy of Allergic Diseases.Frontiers in microbiology · 2018Review
- Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development.Current medicinal chemistry · 2017Review
- Bacteriophages and phage-inspired nanocarriers for targeted delivery of therapeutic cargos.Advanced drug delivery reviews · 2016Review
- Phage display as a promising approach for vaccine development.Journal of biomedical science · 2016Review
- Overview of computational vaccinology: vaccine development through information technology.Journal of applied genetics · 2015Review
- Antigen delivery by filamentous bacteriophage fd displaying an anti-DEC-205 single-chain variable fragment confers adjuvanticity by triggering a TLR9-mediated immune response.EMBO molecular medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The filamentous bacteriophage are highly immunogenic particles that can be used as carrier proteins for peptides and presumably other haptens and antigens. Our previous work demonstrated that the antibody response was better focused against a synthetic peptide if it was conjugated to phage as compared to the classical carrier, ovalbumin. We speculated that this was due, in part, to the relatively low surface complexity of the phage. Here, we further investigate the phage as an immunogenic carrier, and the effect reducing its surface complexity has on the antibody response against peptides that are either displayed as recombinant fusions to the phage coat or are chemically conjugated to it. Immunodominant regions of the minor coat protein, pIII, were removed from the phage surface by excising its N1 and N2 domains (Delta3 phage variant), whereas immunodominant epitopes of the major coat protein, pVIII, were altered by reducing the charge of its surface-exposed N-terminal residues (Delta8 phage variant). Immunization of mice revealed that the Delta3 variant was less immunogenic than wild-type (WT) phage, whereas the Delta8 variant was more immunogenic. The immunogenicity of two different peptides was tested in the context of the WT and Delta3 phage in two different forms: (i) as recombinant peptides fused to pVIII, and (ii) as synthetic peptides conjugated to the phage surface. One peptide (MD10) in its recombinant form produced a stronger anti-peptide antibody response fused to the WT carrier compared to the Delta3 phage carrier, and did not elicit a detectable anti-peptide response in its synthetic form conjugated to either phage carrier. This trend was reversed for a different peptide (4E10(L)), which did not produce a detectable anti-peptide antibody response as a recombinant fusion; yet, as a chemical conjugate to Delta3 phage, but not WT phage, it elicited a highly focused anti-peptide antibody response that exceeded the anti-carrier response by approximately 65-fold. The results suggest that focusing of the antibody response against synthetic peptides can be improved by decreasing the antigenic complexity of the phage surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.